Hainan Shuangcheng Pharmaceut
Hainan Shuangcheng Pharmaceuticals Co., Ltd. provides peptide, lyophilized, oncology, oral dosage, and other injection cartridge pharmaceutical products worldwide. The company offers thymalfasin, thymapentin, bortezmib, paclitaxel, somatostatin, pantoprazole, epifibatide, bivalirudin, liraglutide, and exenatide and sodium ferulate for injections, as well as vitamin B6. Hainan Shuangcheng Pharmace… Read more
Hainan Shuangcheng Pharmaceut (002693) - Total Liabilities
Latest total liabilities as of September 2025: CN¥393.42 Million CNY
Based on the latest financial reports, Hainan Shuangcheng Pharmaceut (002693) has total liabilities worth CN¥393.42 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hainan Shuangcheng Pharmaceut - Total Liabilities Trend (2009–2024)
This chart illustrates how Hainan Shuangcheng Pharmaceut's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Hainan Shuangcheng Pharmaceut Competitors by Total Liabilities
The table below lists competitors of Hainan Shuangcheng Pharmaceut ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GuangZhou Wahlap Technology Corporation Limited
SHE:301011
|
China | CN¥564.87 Million |
|
CFM Indosuez Wealth SA
PA:MLCFM
|
France | €5.26 Billion |
|
Okins Electronics Co. Ltd
KQ:080580
|
Korea | ₩55.64 Billion |
|
Inflection Point Acquisition Corp. III Class A Ordinary Shares
NASDAQ:IPCX
|
USA | $14.87 Million |
|
Asure Software Inc
NASDAQ:ASUR
|
USA | $253.99 Million |
|
Logistea AB Series B
ST:LOGI-B
|
Sweden | Skr9.63 Billion |
|
TTK Prestige Limited
NSE:TTKPRESTIG
|
India | ₹7.91 Billion |
|
VT GMP Co.Ltd
KQ:018290
|
Korea | ₩93.15 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Hainan Shuangcheng Pharmaceut's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hainan Shuangcheng Pharmaceut's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hainan Shuangcheng Pharmaceut (2009–2024)
The table below shows the annual total liabilities of Hainan Shuangcheng Pharmaceut from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥372.26 Million | +30.34% |
| 2023-12-31 | CN¥285.60 Million | -13.47% |
| 2022-12-31 | CN¥330.08 Million | +14.69% |
| 2021-12-31 | CN¥287.80 Million | -6.97% |
| 2020-12-31 | CN¥309.37 Million | +13.44% |
| 2019-12-31 | CN¥272.72 Million | -39.47% |
| 2018-12-31 | CN¥450.56 Million | -26.79% |
| 2017-12-31 | CN¥615.41 Million | +0.49% |
| 2016-12-31 | CN¥612.40 Million | -1.63% |
| 2015-12-31 | CN¥622.56 Million | +1145.41% |
| 2014-12-31 | CN¥49.99 Million | +7.68% |
| 2013-12-31 | CN¥46.42 Million | +13.78% |
| 2012-12-31 | CN¥40.80 Million | +105.79% |
| 2011-12-31 | CN¥19.83 Million | -79.11% |
| 2010-12-31 | CN¥94.92 Million | +376.80% |
| 2009-12-31 | CN¥19.91 Million | -- |